{"id":"infusion-intravenous","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypotension"},{"rate":"0.1-1%","effect":"Cardiac arrest"},{"rate":"0.01-0.1%","effect":"Anaphylaxis"}]},"_chembl":null,"_dailymed":{"setId":"259f8ef4-96ac-7213-e063-6394a90adb71","title":"0.9% SODIUM CHLORIDE INJECTION, 1000ML, BLUE PHARMA, TOTALCARE (SODIUM CHLORIDE 0.9% W/V FOR INTRAVENOUS INFUSION) INJECTION, SOLUTION 0.9% SODIUM CHLORIDE INJECTION, 1000ML, DRE BIOLAB, TOTALCARE (SODIUM CHLORIDE 0.9% W/V FOR INTRAVENOUS INFUSION) INJECTION, SOLUTION 0.9% SODIUM CHLORIDE INJECTION, 500ML, DRE BIOLAB, TOTALCARE (SODIUM CHLORIDE 0.9% W/V FOR INTRAVENOUS INFUSION) INJECTION, SOLUTION 0.9% SODIUM CHLORIDE INJECTION, 500ML, BLUE PHARMACEUTICALS, TOTALCARE (SODIUM CHLORIDE 0.9% W/V FOR INTRAVENOUS INFUSION) INJECTION, SOLUTION [AMCO INTERNATIONAL CORP]"},"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This allows for rapid and targeted delivery of the substance, which can be particularly effective in emergency situations or when a rapid response is needed.","oneSentence":"Infusion Intravenous works by delivering a specific substance directly into the bloodstream.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:36:25.687Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Emergency treatment of severe hypotension"}]},"trialDetails":[{"nctId":"NCT07148089","phase":"PHASE1","title":"A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)","status":"RECRUITING","sponsor":"Solid Biosciences Inc.","startDate":"2026-02-23","conditions":"Catecholaminergic Polymorphic Ventricular Tachycardia","enrollment":18},{"nctId":"NCT07497009","phase":"NA","title":"Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial.","status":"COMPLETED","sponsor":"Benha University","startDate":"2024-12-23","conditions":"Neurocognitive Function of Elderly Patients Post Operation","enrollment":30},{"nctId":"NCT07498595","phase":"EARLY_PHASE1","title":"TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2026-03-31","conditions":"EGFR-TKI-resistant Non-Small Cell Lung Cancer","enrollment":50},{"nctId":"NCT06925737","phase":"PHASE3","title":"A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-13","conditions":"Prostate Cancer, Prostatic Neoplasms","enrollment":1440},{"nctId":"NCT06941272","phase":"PHASE1, PHASE2","title":"A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-26","conditions":"Malignant Neoplasm","enrollment":50},{"nctId":"NCT07155174","phase":"PHASE2","title":"A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-11-25","conditions":"Small Cell Lung Cancer","enrollment":180},{"nctId":"NCT04884594","phase":"PHASE1","title":"AAV8-hCocH for Cocaine Use Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"W. Michael Hooten","startDate":"2021-10-08","conditions":"Cocaine Dependence, in Remission","enrollment":10},{"nctId":"NCT04569591","phase":"NA","title":"DDAVP for Pituitary Adenoma","status":"RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2026-03-09","conditions":"Cushing's Disease, Pituitary Adenoma","enrollment":22},{"nctId":"NCT07357909","phase":"PHASE1","title":"Safety Study of Intravenous Hydrogen-Oxygen Ultrafine Bubbles in Adults","status":"NOT_YET_RECRUITING","sponsor":"Yayasan Inovasi Molekuler Indonesia (Indonesia Molecular Innovation Foundation)","startDate":"2026-05-01","conditions":"Healthy Volunteer","enrollment":50},{"nctId":"NCT06841354","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-16","conditions":"Triple Negative Breast Neoplasms","enrollment":1000},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT04524871","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-11-01","conditions":"Advanced Liver Cancers","enrollment":518},{"nctId":"NCT07494435","phase":"PHASE2","title":"Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Haichang Biotech Co., Ltd.","startDate":"2026-06-01","conditions":"Hepato Cellular Carcinoma (HCC), Renal Cell Cancer","enrollment":230},{"nctId":"NCT07024784","phase":"PHASE2","title":"A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-07-30","conditions":"Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer","enrollment":377},{"nctId":"NCT05139017","phase":"PHASE2, PHASE3","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-14","conditions":"DLBCL, Diffuse Large B-Cell Lymphoma","enrollment":290},{"nctId":"NCT06154252","phase":"PHASE2, PHASE3","title":"RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy","status":"RECRUITING","sponsor":"Cabaletta Bio","startDate":"2023-12-20","conditions":"Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome","enrollment":74},{"nctId":"NCT06459180","phase":"PHASE3","title":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-24","conditions":"Cervical Cancer","enrollment":686},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT04097561","phase":"PHASE1","title":"Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-01-13","conditions":"Idiopathic CD4 Lymphopenia","enrollment":20},{"nctId":"NCT03620019","phase":"PHASE2","title":"Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2018-09-10","conditions":"Melanoma Stage Iii, Melanoma Stage Iv, Melanoma","enrollment":25},{"nctId":"NCT07496593","phase":"PHASE4","title":"Total Intravenous and Balanced Anesthesia in Diabetic Patients Undergoing Video-Assisted Thoracoscopy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ain Shams University","startDate":"2025-12-01","conditions":"Diabete Mellitus, VATS, TIVA","enrollment":60},{"nctId":"NCT03236428","phase":"PHASE2","title":"Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-11-24","conditions":"Monoclonal Gammopathy, Smoldering Multiple Myeloma","enrollment":42},{"nctId":"NCT07496008","phase":"","title":"Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population","status":"NOT_YET_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-03-25","conditions":"Isavuconazole, Invasion Pulmonary Mycosis","enrollment":150},{"nctId":"NCT07191652","phase":"","title":"The Relationship Between Opioid-Free Anesthesia and Postoperative Agitation-Delirium and Quality of Recovery in Pediatric Ear, Nose, and Throat Cases Monitored With Perioperative Bispectral Index","status":"RECRUITING","sponsor":"Istanbul University - Cerrahpasa","startDate":"2026-03-25","conditions":"Ear Throat Nose Surgery, Delirium - Postoperative, Pain Postoperative","enrollment":120},{"nctId":"NCT06305754","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-11","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":520},{"nctId":"NCT07247110","phase":"PHASE1","title":"A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-16","conditions":"Malignant Neoplasm","enrollment":250},{"nctId":"NCT07189871","phase":"PHASE1, PHASE2","title":"177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Radiopharm Theranostics, Ltd","startDate":"2026-02-23","conditions":"Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer)","enrollment":61},{"nctId":"NCT07495150","phase":"NA","title":"Intracalvariosseous Plus Intravenous Antibiotics for Moderate-to-Severe Bacterial Meningitis","status":"NOT_YET_RECRUITING","sponsor":"yilong Wang","startDate":"2026-04-01","conditions":"Blood-Brain Barrier, Bacterial Meningitis","enrollment":86},{"nctId":"NCT07113691","phase":"PHASE1","title":"Iadademstat + SBRT With Atezo in ES-SCLC","status":"RECRUITING","sponsor":"Yale University","startDate":"2026-01-20","conditions":"Extensive Stage Small Cell Lung Cancer (ES-SCLC)","enrollment":15},{"nctId":"NCT07494084","phase":"PHASE4","title":"Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance","status":"NOT_YET_RECRUITING","sponsor":"Washington State University","startDate":"2026-05-01","conditions":"Shift Work Schedule, Circadian Rhythm, Insulin Resistance","enrollment":24},{"nctId":"NCT04199104","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-05","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":511},{"nctId":"NCT04404881","phase":"PHASE2","title":"Bevacizumab In Hereditary Hemorrhagic Telangiectasia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hanny Al-Samkari, MD","startDate":"2020-11-23","conditions":"Hereditary Hemorrhagic Telangiectasia","enrollment":33},{"nctId":"NCT06824467","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-09","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":770},{"nctId":"NCT07489287","phase":"PHASE1","title":"GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer","status":"NOT_YET_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-06-15","conditions":"Platinum-resistant Ovarian Cancer","enrollment":18},{"nctId":"NCT07465276","phase":"PHASE2","title":"Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2026-03-26","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC), Squamous Cell Carcinoma of the Head and Neck","enrollment":32},{"nctId":"NCT06295809","phase":"PHASE2, PHASE3","title":"A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-18","conditions":"Carcinoma, Squamous Cell, Skin Neoplasms","enrollment":46},{"nctId":"NCT04847063","phase":"PHASE1","title":"Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-19","conditions":"Peritoneal Mesothelioma, Peritoneal Carcinomatosis, Ovarian Cancer","enrollment":60},{"nctId":"NCT03969004","phase":"PHASE3","title":"Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2019-06-04","conditions":"Cutaneous Squamous Cell Carcinoma","enrollment":415},{"nctId":"NCT06128629","phase":"PHASE3","title":"MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)","status":"RECRUITING","sponsor":"Intellia Therapeutics","startDate":"2023-12-13","conditions":"Transthyretin Amyloidosis (ATTR) With Cardiomyopathy","enrollment":1200},{"nctId":"NCT05949554","phase":"","title":"Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.","status":"WITHDRAWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-09","conditions":"Neuropathic Pain","enrollment":""},{"nctId":"NCT06858579","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)","status":"RECRUITING","sponsor":"Dianthus Therapeutics","startDate":"2025-02-10","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":480},{"nctId":"NCT07497984","phase":"","title":"ITM11 Expanded Access Program","status":"AVAILABLE","sponsor":"ITM Solucin GmbH","startDate":"","conditions":"Meningioma","enrollment":""},{"nctId":"NCT06854640","phase":"PHASE1","title":"A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy","status":"RECRUITING","sponsor":"Bayer","startDate":"2025-03-12","conditions":"Sepsis, Coagulopathy","enrollment":36},{"nctId":"NCT06439082","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-10-24","conditions":"Sickle Cell Disease","enrollment":315},{"nctId":"NCT04785820","phase":"PHASE2","title":"A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-06-25","conditions":"Advanced or Metastatic Esophageal Squamous Cell Carcinoma","enrollment":190},{"nctId":"NCT04351256","phase":"PHASE2","title":"Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy","status":"COMPLETED","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2020-05-20","conditions":"NSCLC, Stage III","enrollment":51},{"nctId":"NCT06422143","phase":"PHASE3","title":"Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-10","conditions":"Non-small Cell Lung Cancer, NSCLC","enrollment":851},{"nctId":"NCT07459166","phase":"PHASE2","title":"A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade","status":"NOT_YET_RECRUITING","sponsor":"Clear Scientific, Inc.","startDate":"2026-04","conditions":"Fentanyl Overdose, Fentanyl Poisoning","enrollment":16},{"nctId":"NCT06698796","phase":"PHASE3","title":"A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-01-22","conditions":"Dermatomyositis, Polymyositis","enrollment":211},{"nctId":"NCT03297606","phase":"PHASE2","title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-03-23","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":720},{"nctId":"NCT07210515","phase":"PHASE3","title":"Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)","status":"RECRUITING","sponsor":"Ambros Therapeutics, Inc.","startDate":"2026-03","conditions":"Complex Regional Pain Syndrome Type I","enrollment":270},{"nctId":"NCT01176006","phase":"PHASE2","title":"Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-05","conditions":"DOCK8 Deficiency","enrollment":70},{"nctId":"NCT07494981","phase":"","title":"Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations","status":"NOT_YET_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-03-25","conditions":"Ceftazidime-avibactam","enrollment":150},{"nctId":"NCT07371585","phase":"PHASE2","title":"Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management","status":"RECRUITING","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2026-02-18","conditions":"Breast Cancer Stage IV","enrollment":300},{"nctId":"NCT07497542","phase":"PHASE3","title":"Normal Saline Infusion After Intravenous Thrombolysis in Stroke","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2026-04","conditions":"Brain Infarction","enrollment":752},{"nctId":"NCT06223516","phase":"PHASE1","title":"Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2024-06-17","conditions":"Multiple Myeloma","enrollment":60},{"nctId":"NCT07436728","phase":"PHASE1, PHASE2","title":"A Study of TAK-505 in Adults With Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Takeda","startDate":"2026-04-15","conditions":"Malignant Solid Tumors","enrollment":151},{"nctId":"NCT03783000","phase":"PHASE1","title":"A Study in Healthy Men to Measure the Amount of BI 425809 in the Blood When Taken as a Tablet","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-01-15","conditions":"Healthy","enrollment":6},{"nctId":"NCT03328026","phase":"PHASE1, PHASE2","title":"Combination Study of SV-BR-1-GM With Retifanlimab","status":"COMPLETED","sponsor":"BriaCell Therapeutics Corporation","startDate":"2018-03-16","conditions":"Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer","enrollment":36},{"nctId":"NCT04576117","phase":"PHASE3","title":"A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-16","conditions":"Recurrent Low Grade Astrocytoma, Recurrent WHO Grade 2 Glioma, Refractory Low Grade Astrocytoma","enrollment":300},{"nctId":"NCT07197450","phase":"EARLY_PHASE1","title":"Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-05-20","conditions":"Hypoparathyroidism","enrollment":6},{"nctId":"NCT07172919","phase":"PHASE2","title":"A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation","status":"RECRUITING","sponsor":"Amgen","startDate":"2026-01-02","conditions":"Advanced Solid Tumors","enrollment":14},{"nctId":"NCT05071222","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-19","conditions":"Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency","enrollment":7},{"nctId":"NCT07259317","phase":"PHASE2","title":"Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Corcept Therapeutics","startDate":"2026-01-27","conditions":"Adenocarcinoma, Carcinoma, Pancreatic Ductal","enrollment":60},{"nctId":"NCT06953323","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors","status":"RECRUITING","sponsor":"Wigen Biomedicine Technology (Shanghai) Co., Ltd.","startDate":"2025-07-10","conditions":"Advanced Solid Tumor","enrollment":86},{"nctId":"NCT06312176","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-14","conditions":"Breast Neoplasms","enrollment":1200},{"nctId":"NCT06696768","phase":"PHASE1","title":"Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-23","conditions":"Metastatic Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8","enrollment":24},{"nctId":"NCT06533865","phase":"PHASE3","title":"Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-03-19","conditions":"FHA (Functional Hypothalamic Amenorrhea)","enrollment":114},{"nctId":"NCT04633252","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-23","conditions":"Cancer Of Prostate, Prostate Neoplasms","enrollment":86},{"nctId":"NCT06628310","phase":"PHASE2","title":"A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-12-13","conditions":"Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma","enrollment":180},{"nctId":"NCT06132256","phase":"PHASE2","title":"MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Syndax Pharmaceuticals","startDate":"2023-12-11","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":145},{"nctId":"NCT05226117","phase":"PHASE2","title":"Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2022-03-23","conditions":"Urothelial Carcinoma","enrollment":44},{"nctId":"NCT06041516","phase":"PHASE1","title":"A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-17","conditions":"Neuroendocrine Carcinomas, Neuroendocrine Tumors, Carcinoma, Neuroendocrine","enrollment":70},{"nctId":"NCT06904066","phase":"PHASE1","title":"Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic","enrollment":86},{"nctId":"NCT03569891","phase":"PHASE3","title":"HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2018-06-27","conditions":"Hemophilia B","enrollment":67},{"nctId":"NCT06969807","phase":"PHASE2","title":"Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-06-09","conditions":"Diabetic Kidney Disease (DKD)","enrollment":120},{"nctId":"NCT04214249","phase":"PHASE2","title":"BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-17","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":49},{"nctId":"NCT07497438","phase":"PHASE3","title":"Comparison of Two Etoposide Initiation Strategies for Severe Hemophagocytic Lymphohistiocytosis","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-04","conditions":"Hemophagocytic Lymphohistiocytosis","enrollment":176},{"nctId":"NCT07273071","phase":"PHASE4","title":"Individualized Multiplex Pathophysiological Treatment of Severe Acute Infections: N-Acetylcysteine","status":"NOT_YET_RECRUITING","sponsor":"Theis S. Itenov","startDate":"2026-07","conditions":"Sepsis, Acute Infection, Severe Infection","enrollment":360},{"nctId":"NCT05896163","phase":"PHASE1, PHASE2","title":"A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-08-30","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":30},{"nctId":"NCT06843447","phase":"PHASE1, PHASE2","title":"A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-15","conditions":"Ovarian Cancer Recurrent","enrollment":280},{"nctId":"NCT07495449","phase":"NA","title":"Effect of Infusion Warming on Mannitol Infusion Pain in Patients With Acute Ocular Hypertension","status":"COMPLETED","sponsor":"Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong","startDate":"2025-01-09","conditions":"Acute Ocular Hypertension Glaucoma, Intraocular Hypertension, Primary Angle-Closure Glaucoma","enrollment":142},{"nctId":"NCT07043725","phase":"PHASE3","title":"A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-09-15","conditions":"HER2-positive Breast Cancer","enrollment":544},{"nctId":"NCT07494448","phase":"PHASE1, PHASE2","title":"Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"MedSIR","startDate":"2026-07-01","conditions":"HER 2 Positive Advanced Breast Cancer, Breast Cancer","enrollment":24},{"nctId":"NCT04251533","phase":"PHASE3","title":"Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-06-08","conditions":"Triple Negative Breast Neoplasms","enrollment":137},{"nctId":"NCT06290141","phase":"PHASE3","title":"A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-08-21","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":160},{"nctId":"NCT05907122","phase":"PHASE3","title":"A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-07-26","conditions":"Melanoma","enrollment":256},{"nctId":"NCT04482309","phase":"PHASE2","title":"A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-08-18","conditions":"Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer","enrollment":477},{"nctId":"NCT06717347","phase":"PHASE3","title":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-01-27","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1046},{"nctId":"NCT06743009","phase":"NA","title":"Metabolic Effects of the Exercise-metabolite Lac-Phe","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2025-05-13","conditions":"Healthy Overweight/Obese","enrollment":23},{"nctId":"NCT04826341","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-09-20","conditions":"HRD Cancer, SCLC, Advanced Solid Tumors","enrollment":120},{"nctId":"NCT01303146","phase":"PHASE2","title":"Efficacy METAZYM for the Treatment Metachromatic Leukodystrophy Treated With Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-10","conditions":"Metachromatic Leukodystrophy","enrollment":1},{"nctId":"NCT05039840","phase":"PHASE2","title":"Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2021-11-10","conditions":"Systemic Lupus Erythematosus","enrollment":109},{"nctId":"NCT07285460","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-12-18","conditions":"Hemophilia","enrollment":85},{"nctId":"NCT06312137","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-03","conditions":"Non Small Cell Lung Cancer","enrollment":780},{"nctId":"NCT06395103","phase":"PHASE1, PHASE2","title":"Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-08-16","conditions":"B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma","enrollment":90},{"nctId":"NCT07318558","phase":"PHASE3","title":"A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-02-16","conditions":"Ovarian Neoplasms, Ovarian Cancer","enrollment":900},{"nctId":"NCT07498439","phase":"EARLY_PHASE1","title":"TILs Therapy for Multiple Primary Early-Stage NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2026-03-31","conditions":"Primary Early-stage Non-small Cell Lung Cancer","enrollment":50},{"nctId":"NCT07498673","phase":"EARLY_PHASE1","title":"A Study of YKST02 in Participants With Primary IgA Nephropathy","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-03-31","conditions":"Primary IgA Nephropathy","enrollment":12},{"nctId":"NCT07037758","phase":"PHASE1","title":"A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)","status":"RECRUITING","sponsor":"Amgen","startDate":"2025-09-16","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":380}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":111,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Analgesics and sedatives intravenous continuous infusion"],"phase":"marketed","status":"active","brandName":"Infusion Intravenous","genericName":"Infusion Intravenous","companyName":"Poznan University of Medical Sciences","companyId":"poznan-university-of-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Infusion Intravenous works by delivering a specific substance directly into the bloodstream. Used for Emergency treatment of severe hypotension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}